BIOMAT Database Logo BIOMAT Database Logo

The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. 1997

S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
Department of Medicine V and PET Centre, Aarhus University Hospital, Denmark.

BACKGROUND Prophylactic treatment with ursodeoxycholic acid (UDCA) has been reported to reduce the incidence of acute rejection after liver transplantation compared with historical controls. We investigated this in a prospective, randomized, placebo-controlled multicenter study. METHODS Fifty-four liver transplant patients were allocated to the UDCA treatment group (15 mg/kg/day), and 48 patients were allocated to the placebo group. Trial medicine was started on the first postoperative day and was given for 3 months. Follow-up was for 12 months. Treatment was stratified for adults with chronic liver disease (n=77), adults with acute liver failure (n=10), and children (n=15). RESULTS The frequency of patients with acute rejection was 65% in the UDCA treatment group and 68% in the placebo group. The frequency of steroid-resistant rejection was similar in both groups. The probability of acute rejection, analyzed according to the intention-to-treat policy with Kaplan-Meier analysis, was similar in both treatment groups. No significant differences were found in patient survival and graft survival probabilities. For the biochemical markers of cholestasis, only gamma-glutamyltransferase was significantly improved after 2 months of UDCA treatment. CONCLUSIONS The initial optimistic report of a beneficial effect of prophylactic treatment with UDCA on acute rejection after liver transplantation was not confirmed in this controlled study.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005723 gamma-Glutamyltransferase An enzyme, sometimes called GGT, with a key role in the synthesis and degradation of GLUTATHIONE; (GSH, a tripeptide that protects cells from many toxins). It catalyzes the transfer of the gamma-glutamyl moiety to an acceptor amino acid. GGTP,Glutamyl Transpeptidase,gammaglutamyltransferase,gamma-Glutamyl Transpeptidase,Transpeptidase, Glutamyl,Transpeptidase, gamma-Glutamyl,gamma Glutamyl Transpeptidase,gamma Glutamyltransferase
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections

Related Publications

S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
May 1994, Hepatology (Baltimore, Md.),
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.
November 1999, Annals of internal medicine,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial.
May 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection.
July 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
August 2023, Movement disorders : official journal of the Movement Disorder Society,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.
September 1995, Hepatology (Baltimore, Md.),
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial.
February 2012, Journal of the American College of Cardiology,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
September 2016, Journal of hepatology,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
June 2007, Transplantation,
S Keiding, and K Høckerstedt, and K Bjøro, and S Bondesen, and A Hjortrup, and H Isoniemi, and C Erichsen, and G Söderdahl, and B G Ericzon
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.
August 2010, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!